Reprolab - Company finances
|
EUR
|
2022
From: 2022-07-27
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|
|
Financial data
|
||||
| Sales revenue | 4,828 | 27,255 | 37,067 | 34,124 |
| Profit before tax | 923 | 6,394 | -1,963 | -1,661 |
| Net profit | 923 | 6,394 | -1,963 | -1,661 |
| Equity | 923 | 7,316 | 5,033 | 3,372 |
| Liabilities | 1,000 | 2,809 | 2,269 | 2,083 |
| Non-current assets | 0 | 0 | 0 | 0 |
| Current assets | 1,923 | 10,125 | 7,302 | 5,455 |
| Total assets | 1,923 | 10,125 | 7,302 | 5,455 |
|
Taxes paid
|
||||
| STI taxes | - | 144 | 576 | 246 |
|
Financial indicators
|
||||
| Revenue change y/y | - | +464.5% | +36.0% | -7.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 48.0% | 63.2% | -26.9% | -30.4% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 100.0% | 87.4% | -39.0% | -49.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 19.1% | 23.5% | -5.3% | -4.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 19.1% | 23.5% | -5.3% | -4.9% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 1.1 | 0.4 | 0.5 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Reprolab - Social security debts
The company had no debts to Sodra
Reprolab - VMI tax arrears
The company had no tax arrears (debts) to the State Tax Inspectorate
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Reprolab, MB (code 306121613) is a Small partnership engaged in Veterinary activities. In 2025, the company generated revenue of €34.1K, down 7.9% year on year, but still above the 2023 level of €27.3K, which indicates a two-year increase of 25.2%. Profitability remained negative in 2025, with net loss of €1.7K and a profit margin of -4.9%. This followed a profitable 2023, when net profit reached €6.4K and the margin was 23.5%, and a weaker 2024 result, when revenue rose to €37.1K but the company posted a €2.0K loss. The balance sheet also contracted over the period: total assets declined from €10.1K in 2023 to €7.3K in 2024 and €5.5K in 2025, while equity decreased from €7.3K to €3.4K. Liabilities were contained at €2.1K in 2025. Latest ratios show an equity ratio of 61.8%, debt-to-equity of 0.62, asset turnover of 6.26x, ROE of -49.3% and ROA of -30.4%.